slides · global inventory
Comparison Frame
Framework collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 6,294
Current window 4,591-4,620
Pages 210
Rows per page 30
Framework
4,591-4,620 of 6,294
08
The chart uses a visual metaphor of a 'ceiling' (the 40% remission line) and an arrow to indicate the desired shift in therapeutic performance.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Golden Circle1 hit
16
The chart uses a dual-axis approach to imply a safety-efficacy trade-off, positioning vedolizumab as the 'safest' and highly effective.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
17
The slide uses a checkmark/empty circle matrix to highlight competitive differentiation.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
23
The slide uses a visual timeline/comparison to contrast the competitor's high-frequency, citrate-containing formulation with the company's low-frequency, citrate-free formulation.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
28
The slide uses a comparison table to establish competitive positioning.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
31
The chart uses a horizontal bar format to compare clinical remission percentages across different drug targets (TL1A, a4b7, IL-23s, TNFa, S1P1s, JAKs).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
32
The slide uses a checkmark matrix to highlight the superiority of SPY002.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
34
Includes visual representation of antibody binding mechanisms.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
40
The chart uses a waterfall-style logic to show the additive effect of the combination therapy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
41
The slide uses donut charts to represent remission rates and highlights the safety advantages of gut-selective backbones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
45
The slide uses a comparative framework to validate the efficacy of CDx-guided patient selection.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
49
The chart uses a custom range bar (min/max) with markers for IPO and Today's market cap.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
50
The slide uses a timeline-based comparison to suggest that Spyre's assets are on a similar trajectory to high-value acquired assets.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
09
The chart shows a clear divergence between CPF's deposit costs and the peer average, particularly in recent periods.Central Pacific Financial | Results Presentation Deck | 19 slides · Central Pacific Financial
Conference presentation Investor relations Beat · Financials1 hit
08
The slide uses a comparison framework to contrast existing treatments for other conditions with the lack of treatments for FSAD.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
11
Includes a visual comparison indicating FSAD is not equal to HSDD.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
05
The slide uses a contrast-pairs framework to differentiate the company's core offering from the incumbent market standard.Deliveroo | Investor Event Presentation Deck | 27 slides · Deliveroo
Conference presentation Investor relations Beat · Problem1 hit
13
Deliveroo | Investor Event Presentation Deck | 27 slidesDeliveroo | Investor Event Presentation Deck | 27 slides · Deliveroo
Conference presentation Investor relations Loop · Why Now1 hit
40
The table uses a color-coded heatmap (green/yellow/red) to indicate performance against criteria.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
53
The slide uses a color-coded heatmap (green/yellow/red/grey) to visualize performance against target product profile (TPP) criteria.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
The slide uses two distinct chart types to demonstrate credit quality: a grouped bar chart for NPLs/NPAs and a bar chart with trend lines for NCOs.First Foundation | Investor Presentation Deck | 48 slides · First Foundation
Conference presentation Investor relations 1 hit
33
The chart shows FFB Total and FFB Excluding customer service vs Bank Peer group from 2Q21 to 2Q23.First Foundation | Investor Presentation Deck | 48 slides · First Foundation
Conference presentation Investor relations 1 hit
17
The slide uses a cross-trial comparison to highlight the efficacy of Olvi-Vec in heavily pre-treated patients compared to other standard regimens.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
23
The slide uses a dual-axis line chart to show the relationship between deposit costs and the Fed Funds Rate.HBT Financial | Results Presentation Deck | 36 slides · HBT Financial
Conference presentation Investor relations 1 hit
09
The slide uses three side-by-side bar charts to demonstrate dominance in specific financial advisory niches.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Traction1 hit
08
The slide uses a three-column layout to define the company's core identity.Kenvue | Securities Offering Presentation Deck | 35 slides · Kenvue
Regulatory filing Investor relations 1 hit
18
The slide uses a table for portfolio composition and a bar chart for peer benchmarking of office loan exposure.KeyCorp | Results Presentation Deck | 25 slides · KeyCorp
Conference presentation Investor relations Beat · SolutionLoop · Pareto Focus1 hit
10
The chart uses a waterfall-style bridge element to explain the delta in 2023 growth rates.Kinnevik | Results Presentation Deck | 15 slides · Kinnevik
Conference presentation Investor relations Beat · SatisfactionLoop · Logic Chain1 hit
31
Includes specific commentary on Cityblock and VillageMD performance and valuation adjustments.Kinnevik | Results Presentation Deck | 48 slides · Kinnevik
Shareholder letter Investor relations Beat · Appendix DataLoop · Cost Of Inaction1 hit
34
Includes a table comparing investees to peer averages and top quartiles, plus a scatter plot of SaaS Universe vs. Healthcare Technology.Kinnevik | Results Presentation Deck | 48 slides · Kinnevik
Shareholder letter Investor relations Beat · Appendix DataLoop · Cost Of Inaction1 hit